PUF Ventures Inc. (“PUF” or the “Company”) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce that PUF Ventures Australia (“PUFA”) has filed application with the Australian Office of Drug Control to obtain a medicinal cannabis license and a cannabis research license in collaboration with the National Institute of Complementary Medicine (NICM), an Australian Health Research Institute based at Western Sydney University in New South Wales (NSW), Australia.
PUF Ventures Australia aims to conduct medical research with NICM’s academic input at its proposed Northern Rivers Project, in a 10,000-square foot dedicated laboratory, training center and research facility. When complete the facility will include an extensive 1,200,000 square feet medicinal cannabis cultivation greenhouse and extraction plant, to be located near Casino, NSW. PUF Ventures Inc. and MYM Nutraceutical are partners in the Northern Rivers Project.
“NICM is a world-class research institute, and this collaboration will allow for access to our planned state-of-the-art labs and greenhouse facilities,” said Michael Horsfall, CEO, PUF Ventures Australia. “NICM will provide their independent academic expertise to contribute to PUFA’s research agenda. This is a significant step forward to allow PUF Ventures Australia to focus on its mandate to develop innovative medicinal products.”
Professor Jerome Sarris, NICM Deputy Director sees tremendous mutual value in this evolving research relationship.
“As an institute specializing in medicinal plant research, to collaborate with an organization such as PUF Ventures Australia, with a grand and inspiring vision, holds significant medical potential,” said Professor Sarris. “There is a growing global appetite for ‘clean-green’ high-quality medicinal plants, and in particular, medicinal cannabis, which presents immense health opportunities. NICM engages in selective research collaborations in medicinal cannabis, and the PUFA Northern Rivers Project is a significant development in the field which we are proud to be involved with.”
The Northern Rivers Project is working with experts in AustraliaEurope, and Canada in support of the application with the Australian government. The application will further scientific and medical research in the field of medicinal cannabis. PUF Ventures Australia is presently in discussions with NICM on a range of potential projects including women’s health disorders, multiple sclerosis, immune disorders, and the optimization of cannabis constituent profiles.
About NICM
Western Sydney University’s NICM is Australia’s leader in integrative and complementary medicine research and policy. Seed funded by the Commonwealth and NSW State Governments, NICM plays a key national role in ensuring Australians have access to reliable evidence on complementary medicines and treatments in wide use. As an ERA 5 ranking institute, NICM is globally recognized for its world-class research and innovations in integrative and complementary medicine. More information is available at www.nicm.edu.au.
About Northern Rivers Project
The Northern Rivers Project is a joint venture between PUF Ventures, PUF Ventures Australia, and MYM Nutraceutical, to build a 1.2 million square foot greenhouse operation on a 27-hectare parcel of land near the town of Casino in northern New South Wales, Australia. The operation when complete will include large-scale greenhouse, manufacturing, processing and office facilities for the cultivation, production and manufacture of medical cannabis and associated products in Australia.  The first phase of the project will cover approximately 300,000 square feet, which will be the largest medical cannabis greenhouse in Australia.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in CanadaGermany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, PUF Ventures Australia, Weed Points Loyalty Inc., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Currently, AAA Heidelberg has not received a license from Health Canada. PUF is publicly traded under the following symbols: CSE: PUF, Frankfurt: PU3 and OTCPK: PUFXF. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
Click here to connect with PUF Ventures Inc. (CSE: PUF) for an Investor Presentation

Source: www.newswire.ca

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less